Seems to me that doctors are business men first. Why else would the quality of care one receives depend on one's ability to pay.
Extending the concept: Each cancer patient is a revenue stream. Why would an oncologist give it up to a radiation oncologist when he doesn't have to. The trick is to force their hand - but how. It's a tough problem, the Bexxar people couldn't figure that one out either,
Can't think of another explanation.
Thanks for the information. Presumably, then, the company knows already and is drafting a press release. Surprised that (a) they don't have one ready to go to shout good news from the roof tops or (b) it isn't good news. Probably over-analyzing this.
Looks like the market thinks approval is as likely as not. Given that the FDA already knows the trial results on which the decision is based, the market should (in my view) have given greater weight to the December PDUFA date than it did. Clearly the market does not see things the way I do. Being that the market (if efficient) is right, I am left with a bunch of questions. Would appreciate some help answering the following:
What are the chances of a favorable advisory board recommendation that supports approval on the PDUFA date? What are the major decision variables the board will consider? What is the most likely recommendation? Thanks.
"I don't understand your post."
The company has negotiated with the FDA at length to get special dispensation to combine the data from the prior two trials to support a NDA. It stands to reason that the FDA gave permission only on the strength of that trial data; there is nothing else to justify this unusual step by the FDA.
Plausible. Still, I took the settlement as a positive; a potential problem removed for chump change. Funny how people look at the same stuff and see very different things.
"...and yet he nor any other officer or director ever put their money where their mouth is..."
I wondered about that too. Came up with a (I think) plausible explanation. The people working for the company and on the BOD are not rich. For example the CEO's wealth comes from the SPPI shares he already owns. Now, if this guy already has 1 million shares and has maybe $100,000 a year (as a guess) left from his salary after living expenses each year he could indeed buy another 25,000 shares - but he would be far more prudent to buy something else and not put all his eggs in one basket. Diversification is a reasonable investment approach for him/them as it is for anyone else.
As long as they don't sell what they already have, I'm content to hold mine too - but I remember what happened when Raj sold the last time. I thought that was a shady move.
The sizzle sounds lovely... It always has ... Many times before... It's time for some steak now. Hope they finally serve it up.
"Boards not a joke. It doesn't take a genius to sort thru the noise."
But it's often ridiculous and sorting through the noise can definitely take unwavering determination. Keep on trucking...
"how could this biotech be trading so far under double-digit stock price levels?"
This is a very thinly traded stock. A few thousand shares can move the share price. As long as there are no earnings the professional traders can walk the share price up or down as they will. That may not change until Apaziquone (or one of the other big ones) is approved, but any short still hanging around when that happens will be squeezed.
We could see a run-up as December 9th approaches. It will only last though if approval happens. Having said that, I would not be short this stock; they have too many shots on goal and know how to get drugs approved. The odds of at least one of the three big ones to be approved are overwhelming.
Do you think they'll release the SPI-2012 data before the NDA? I seem t remember some hesitation about that during the last conference call.